Adimab is a premier biologics discovery and engineering company specializing in antibodies and multispecifics. Leveraging a proprietary yeast-based platform with fully human synthetic and immunized diversity, Adimab delivers high-quality therapeutic leads with exceptional specificity and developability. Over 15 years, Adimab has partnered with industry leaders to advance more than 600 therapeutic programs. Its expertise spans IgG and HCAb discovery, protein therapeutic engineering, and multispecific generation, including a cutting-edge T cell engager platform, making it a trusted partner in therapeutic innovation.